← Back
Data updated: Mar 10, 2026
Roche
RHHBY OncologyNeurologyOphthalmology
Swiss pharma-diagnostics leader known for oncology and diagnostics integration. Key franchises include Tecentriq, Hemlibra, and Ocrevus. Pioneer in personalized medicine.
$66.4B
Revenue (2024)
$240.0B
Market Cap
-
Trials
70
Approved (2yr)
Key Drugs
Recent Activity
EVRYSDI 2026-02-10
Labeling
EVRYSDI 2026-02-10
Labeling
EVRYSDI 2026-01-21
Labeling
EVRYSDI 2026-01-21
Labeling
EVRYSDI 2026-01-21
Labeling
LUNSUMIO 2025-12-19
Efficacy
GAZYVA 2025-12-17
Labeling
ACTEMRA 2025-12-10
Labeling
ACTEMRA 2025-12-10
Labeling
TECENTRIQ HYBREZA 2025-11-24
Efficacy
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 64%
16 drugs Phase 3: 103 Phase 2: 74 Phase 1: 168
Neurology 13%
1 drugs Phase 3: 30 Phase 2: 12 Phase 1: 18
Ophthalmology 10%
2 drugs Phase 3: 21 Phase 2: 8 Phase 1: 13
Immunology 8%
2 drugs Phase 3: 12 Phase 2: 16 Phase 1: 10
Respiratory 5%
3 drugs Phase 3: 6 Phase 2: 9 Phase 1: 6
Pipeline Strength Pro
Loading...
Competitors Pro
Active (38)
ITOVEBI OCREVUS ZUNOVO TECENTRIQ HYBREZA PIASKY COLUMVI LUNSUMIO VABYSMO SUSVIMO ENSPRYNG EVRYSDI PHESGO ROZLYTREK POLIVY HERCEPTIN HYLECTA XOFLUZA HEMLIBRA RITUXAN HYCELA OCREVUS TECENTRIQ ALECENSA COTELLIC GAZYVA KADCYLA PERJETA ERIVEDGE ZELBORAF ACTEMRA LUCENTIS AVASTIN XOLAIR TNKASE HERCEPTIN RITUXAN NUTROPIN AQ NUSPIN CELLCEPT PULMOZYME ACTIVASE CATHFLO ACTIVASE
Discontinued (57)
NUTROPIN AQ PEN NUTROPIN AQ VALIUM BONIVA TAMIFLU INVIRASE CYTOVENE FUZEON ROCEPHIN KIT ROCEPHIN DEMADEX KLONOPIN RAPIDLY DISINTEGRATING NUTROPIN COPEGUS TORADOL KYTRIL LARIAM ACCUTANE ROMAZICON FORTOVASE ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER FANSIDAR AEROBID HIVID TICLID LORFAN GANTANOL-DS GANTANOL VERSED LARODOPA TRIMPEX 200 TRIMPEX TARACTAN GANTRISIN GANTRISIN PEDIATRIC LIPO GANTRISIN NOLUDAR BEROCCA PN SYNKAYVITE MENRIUM 10-4 MENRIUM 5-4 MENRIUM 5-2 RIMADYL TEGISON ENDEP NIPRIDE AZO GANTRISIN ARFONAD EVEX VALRELEASE
+7 more
Company Info
- First Approval
- 1941-07-15
- Latest
- 2026-02-10
- Applications
- 115
FDA Sponsor Names
ROCHEHOFFMANN LA ROCHEGENENTECHROCHE PALOGENENTECH INC +1